SHIFT Newsroom · GLOBAL
Researchers to Study Impact of GLP-1 Receptor Agonists on Intraductal Papillary Mucinous Neoplasms
A new multicentric cohort study aims to investigate the effects of GLP-1 receptor agonists on patients with intraductal papillary mucinous neoplasms
A new study aims to investigate the impact of GLP-1 receptor agonists on patients with intraductal papillary mucinous neoplasms. The study protocol has been published, but the findings are not yet available. The study is still in the research stage and the GLP-1 receptor agonists are not yet licensed or recommended by NICE or the NHS for this use.
What this means in the UK
The study's findings could potentially inform future treatment options for patients with intraductal papillary mucinous neoplasms in the UK, although it is still in the research stage and not yet licensed or recommended by NICE or the NHS
Known facts
- GLP-1 receptor agonists are being studied for their potential impact on intraductal papillary mucinous neoplasms